0001104659-23-004747.txt : 20230118
0001104659-23-004747.hdr.sgml : 20230118
20230118202900
ACCESSION NUMBER: 0001104659-23-004747
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230113
FILED AS OF DATE: 20230118
DATE AS OF CHANGE: 20230118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yang Arvin
CENTRAL INDEX KEY: 0001834321
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38129
FILM NUMBER: 23535722
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mersana Therapeutics, Inc.
CENTRAL INDEX KEY: 0001442836
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-498-0020
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: MERSANA THERAPEUTICS INC
DATE OF NAME CHANGE: 20080813
4
1
tm233833-7_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2023-01-13
0
0001442836
Mersana Therapeutics, Inc.
MRSN
0001834321
Yang Arvin
C/O MERSANA THERAPEUTICS, INC.
840 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
0
1
0
0
SVP, Chief Medical Officer
Common Stock
2023-01-14
4
M
0
7084
0
A
33030
D
Common Stock
2023-01-17
4
S
0
2209
5.74
D
30821
D
Stock option (right to buy)
6.06
2023-01-13
4
A
0
217500
0
A
2033-01-12
Common Stock
217500
217500
D
Restricted stock unit
2023-01-13
4
A
0
48333
0
A
Common Stock
48333
48333
D
Restricted stock unit
2023-01-14
4
M
0
7084
0
D
Common Stock
7084
21249
D
Represents shares of common stock received upon the vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 14, 2022.
Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs reported above. These sales were mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to sell a number of shares of common stock needed to satisfy his tax withholding obligations and does not represent a discretionary trade by the Reporting Person.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $5.74 to $5.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The option shall vest in equal quarterly installments over four years from the date of grant.
Each RSU represents the contingent right to receive one share of common stock of the Issuer.
The RSUs shall vest in equal annual installments over four years from the date of grant.
25% of the total number of RSUs granted vested on January 14, 2023, and the remainder shall vest thereafter in equal annual installments over the next three years.
/s/Alejandra Carvajal, as attorney-in-fact
2023-01-18